Sanofi India Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Sanofi India Stock Forecast and Price Target
If the average 2024 price target of Rp9170.00 recently set by prominent experts for Sanofi India is met, there would be a potential upside of approximately 10.16% from the last closing price in May, 2024. The high estimate is Rp11300.00, and the low is Rp8125.00. If you're looking for information on Sanofi India stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
10.16% Upside
Sanofi India Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Sanofi India's Price has seen a drop from Rp7505.98 to Rp0.00 – a 100.00% decrease. In the next year, analysts believe that Fair Value will reach Rp9551.03 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF89.05 | Buy/Sell | CHF105.00 | 20.85% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$27.18 | Buy/Sell | $32.87 | 12.21% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$277.37 | Buy/Sell | $303.65 | 15.19% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$903.48 | Buy/Sell | $961.26 | 16.22% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£17.05 | Buy/Sell | £17.30 | 14.37% |
Sanofi India Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Sanofi India's Revenue has seen a drop from Rp29.02B to Rp28.51B – a 1.75% decrease. In the next year, analysts believe that Revenue will reach Rp30.19B – an increase of 5.88%. For the next seven years, the forecast is forRevenue to grow by 13.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
8
|
Rp1.50k | Buy/Sell | Rp1.52k | 5.52% |
| CIPLA Stock Forecast | Cipla | Outperform |
18
|
Rp1.40k | Buy/Sell | Rp1.43k | 7.04% |
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp6.21k | Buy/Sell | Rp5.67k | -2.50% |
.jpg)
Sanofi India Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Dividend per Share for Sanofi India has grown by 33.60%, going from Rp125.00 to Rp167.00. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach Rp194.60 – an increase of 16.53%. Over the next seven years, experts anticipate that Dividend per Share growth for Sanofi India will be 17.02%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZYDUSLIFE Stock Forecast | Zydus Lifesciences | Outperform |
18
|
Rp953.55 | Buy/Sell | Rp655.25 | -9.02% |
| 500420 Stock Forecast | Torrent Pharmaceuticals | Outperform |
18
|
Rp2.64k | Buy/Sell | Rp2.13k | 6.04% |
| 500257 Stock Forecast | Lupin | Hold |
12
|
Rp1.65k | Buy/Sell | Rp1.11k | -5.80% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALKEM Stock Forecast | Alkem Laboratories | Hold |
18
|
Rp4.83k | Buy/Sell | Rp4.03k | 9.71% |
| 500488 Stock Forecast | Abbott India | Outperform |
18
|
Rp26.42k | Buy/Sell | Rp24.75k | 11.68% |
| 500660 Stock Forecast | GlaxoSmithKline Pharmaceutical... | Hold |
18
|
Rp2.09k | Buy/Sell | Rp1.78k | 1.10% |
Sanofi India EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Sanofi India's EBITDA has increased by 13.34%, going from Rp7.09B to Rp8.04B. In the next year, analysts are expecting an increase in EBITDA, predicting it will reach Rp8.74B – an increase of 8.73%. The Sanofi India forecast is for EBITDA to reach Rp9.07B or grow by 12.88%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GLENMARK Stock Forecast | Glenmark Pharmaceuticals | Outperform |
18
|
Rp1.06k | Buy/Sell | Rp767.80 | -14.44% |
| 500302 Stock Forecast | Piramal Enterprises | Hold |
18
|
Rp924.90 | Buy/Sell | Rp1.11k | 8.12% |
| PFIZER Stock Forecast | Pfizer | Outperform |
18
|
Rp4.26k | Buy/Sell | Rp4.53k | 15.92% |
Sanofi India EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Sanofi India's EBIT has grown, increasing from Rp6.34B to Rp7.64B – an increase of 20.56%. For next year, the 2 analysts predict EBIT of Rp8.84B, which would mean an increase of 15.73%. Over the next seven years, the pros' prediction is EBITof Rp8.86B, which would mean a seven-year growth forecast of 15.92%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 506820 Stock Forecast | AstraZeneca Pharma India | - |
18
|
Rp5.34k | Buy/Sell | Rp0.00 | -100.00% |
| 500126 Stock Forecast | Procter & Gamble Health | - |
17
|
Rp4.92k | Buy/Sell | Rp5.62k | -100.00% |
| WOCKPHARMA Stock Forecast | Wockhardt | - |
8
|
Rp448.80 | Buy/Sell | Rp0.00 | -100.00% |
Sanofi India EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Sanofi India's EPS has seen a drop from Rp220.44 to Rp0.00 – a 100.00% decrease. In the next year, analysts believe that EPS will reach Rp280.50 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
.jpg)